These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34565708)

  • 21. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
    Zhao Y; Foster NR; Meyers JP; Thomas SP; Northfelt DW; Rowland KM; Mattar BI; Johnson DB; Molina JR; Mandrekar SJ; Schild SE; Bearden JD; Aubry MC; Adjei AA
    J Thorac Oncol; 2015 Jan; 10(1):172-80. PubMed ID: 25247339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal medullary carcinoma: case report and review of the literature.
    Noguera-Irizarry WG; Hibshoosh H; Papadopoulos KP
    Am J Clin Oncol; 2003 Oct; 26(5):489-92. PubMed ID: 14528077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
    Shapiro DD; Zacharias NM; Tripathi DN; Karki M; Bertocchio JP; Soeung M; He R; Westerman ME; Gao J; Rao P; Lam TNA; Jonasch E; Perelli L; Cheng EH; Carugo A; Heffernan TP; Walker CL; Genovese G; Tannir NM; Karam JA; Msaouel P
    Clin Transl Med; 2023 May; 13(5):e1267. PubMed ID: 37226898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
    Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
    Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal medullary carcinoma in a white adolescent with sickle cell trait.
    Daher P; Bourgi A; Riachy E; Khoury A; Rehayem C; Sader-Ghorra C
    J Pediatr Hematol Oncol; 2014 Jul; 36(5):e285-9. PubMed ID: 24517963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal medullary carcinoma: prolonged remission with chemotherapy, immunohistochemical characterisation and evidence of bcr/abl rearrangement.
    Stahlschmidt J; Cullinane C; Roberts P; Picton SV
    Med Pediatr Oncol; 1999 Dec; 33(6):551-7. PubMed ID: 10573578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
    Lai JZ; Lai HH; Cao D
    Anticancer Res; 2018 Jun; 38(6):3757-3761. PubMed ID: 29848739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal medullary carcinoma: A national analysis of 159 patients.
    Ezekian B; Englum B; Gilmore BF; Nag UP; Kim J; Leraas HJ; Routh JC; Rice HE; Tracy ET
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28485059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal medullary carcinoma: case report of an aggressive malignancy with near-complete response to dose-dense methotrexate, vinblastine, Doxorubicin, and Cisplatin chemotherapy.
    Amjad AI; Ali H; Appleman LJ; Maranchie J; Jackman S; Parwani A; Dhir R; Roy S; Parikh RA
    Case Rep Oncol Med; 2014; 2014():615895. PubMed ID: 25215253
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.
    Croghan GA; Suman VJ; Maples WJ; Albertini M; Linette G; Flaherty L; Eckardt J; Ma C; Markovic SN; Erlichman C
    Cancer; 2010 Jul; 116(14):3463-8. PubMed ID: 20564112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive role of PD-L1 expression in the response of renal Medullary carcinoma to PD-1 inhibition.
    Sodji Q; Klein K; Sravan K; Parikh J
    J Immunother Cancer; 2017 Aug; 5(1):62. PubMed ID: 28807004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synchronous bilateral Wilm's tumor with complete radiographic response managed without surgical resection: a report from the National Wilm's Tumor Study 4.
    Hamilton TE; Ritchey ML; Argani P; Beckwith JB; Perlman EJ; Cotton CA; Shamberger RC
    J Pediatr Surg; 2008 Nov; 43(11):1982-4. PubMed ID: 18970928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of a renal medullary carcinoma in an adolescent male with sickle cell trait by Tc-99m methylene disphosponate bone scintigraphy.
    Brown JM; Berkey BD; Brooks JA
    Clin Nucl Med; 2008 Dec; 33(12):896-900. PubMed ID: 19033803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal Medullary Carcinoma with an Aggressive Clinical Course: A Case Report and Review of the Literature.
    Kalavar MR; Ali S; Safarpour D; Kunnakkat SD
    Case Rep Oncol; 2017; 10(1):1-7. PubMed ID: 28203160
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.
    Bylow KA; Atkins MB; Posadas EM; Stadler WM; McDermott DF
    Clin Genitourin Cancer; 2009 Jan; 7(1):39-42. PubMed ID: 19213667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
    Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
    Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens.
    Parma G; Mancari R; Del Conte G; Scambia G; Gadducci A; Hess D; Katsaros D; Sessa C; Rinaldi A; Bertoni F; Vitali A; Catapano CV; Marsoni S; van de Velde H; Colombo N
    Int J Gynecol Cancer; 2012 Jun; 22(5):792-800. PubMed ID: 22635029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.